Gen Wealth Partners Inc Sells 192 Shares of Abbott Laboratories (NYSE:ABT)

Gen Wealth Partners Inc trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 2.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,374 shares of the healthcare product maker’s stock after selling 192 shares during the quarter. Gen Wealth Partners Inc’s holdings in Abbott Laboratories were worth $834,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of ABT. Regent Peak Wealth Advisors LLC lifted its position in shares of Abbott Laboratories by 2.0% during the 4th quarter. Regent Peak Wealth Advisors LLC now owns 4,873 shares of the healthcare product maker’s stock valued at $551,000 after acquiring an additional 97 shares during the period. ORG Wealth Partners LLC lifted its position in Abbott Laboratories by 4.5% during the fourth quarter. ORG Wealth Partners LLC now owns 42,784 shares of the healthcare product maker’s stock worth $4,840,000 after purchasing an additional 1,828 shares during the period. Czech National Bank grew its stake in Abbott Laboratories by 6.1% during the fourth quarter. Czech National Bank now owns 376,065 shares of the healthcare product maker’s stock worth $42,537,000 after buying an additional 21,630 shares in the last quarter. Aprio Wealth Management LLC increased its holdings in Abbott Laboratories by 46.9% in the 4th quarter. Aprio Wealth Management LLC now owns 5,400 shares of the healthcare product maker’s stock valued at $611,000 after buying an additional 1,724 shares during the period. Finally, Clark & Stuart Inc acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at approximately $2,179,000. Institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. Bank of America boosted their price objective on shares of Abbott Laboratories from $133.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Argus upgraded Abbott Laboratories to a “strong-buy” rating in a research report on Tuesday, January 28th. UBS Group lifted their target price on Abbott Laboratories from $146.00 to $148.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Barclays increased their target price on shares of Abbott Laboratories from $158.00 to $159.00 and gave the stock an “overweight” rating in a report on Thursday, April 17th. Finally, StockNews.com lowered shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $142.59.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $133.50 on Friday. The company has a market capitalization of $232.27 billion, a PE ratio of 17.45, a P/E/G ratio of 2.52 and a beta of 0.74. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The company has a 50 day simple moving average of $129.80 and a two-hundred day simple moving average of $123.46.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. Research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be paid a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.77%. The ex-dividend date of this dividend is Tuesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 30.61%.

Insiders Place Their Bets

In related news, Director Sally E. Blount sold 2,600 shares of the business’s stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total transaction of $337,116.00. Following the transaction, the director now owns 34,058 shares in the company, valued at $4,415,960.28. The trade was a 7.09 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the completion of the sale, the executive vice president now owns 71,928 shares of the company’s stock, valued at $9,625,404.96. The trade was a 55.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 95,278 shares of company stock worth $12,745,859. Corporate insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.